Takashi Suzuki

Ogikubo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.

Journal: BMJ open

Published: February 18, 2022

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.

Journal: Human gene therapy

Published: February 14, 2022

Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).

Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 01, 2021

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model.

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model.

Journal: Haematologica

Published: November 27, 2019

New therapeutic directions on hemophilia

New therapeutic directions on hemophilia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 11, 2019

Discrepancies between the one-stage clotting assay and chromogenic assay in patients with hemophilia A receiving standard or extended half-life factor VIII products in clinical settings.

Discrepancies between the one-stage clotting assay and chromogenic assay in patients with hemophilia A receiving standard or extended half-life factor VIII products in clinical settings.

Journal: Thrombosis research

Published: September 25, 2019

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: May 13, 2019

Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia.

Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 21, 2018

Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency

Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: December 12, 2018

Which Aspects of Food Value Promote Consumer Purchase Intent after a Disaster? A Case Study of Salmon Products in Disaster-Affected Areas of the Great East Japan Earthquake.

Which Aspects of Food Value Promote Consumer Purchase Intent after a Disaster? A Case Study of Salmon Products in Disaster-Affected Areas of the Great East Japan Earthquake.

Journal: Foods (Basel, Switzerland)

Published: November 26, 2018

Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.

Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.

Journal: Thrombosis research

Published: October 04, 2018

A combination of oral L-citrulline and L-arginine improved 10-min full-power cycling test performance in male collegiate soccer players: a randomized crossover trial.

A combination of oral L-citrulline and L-arginine improved 10-min full-power cycling test performance in male collegiate soccer players: a randomized crossover trial.

Journal: European journal of applied physiology

Published: June 30, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026